Literature DB >> 8348559

Cytokine combinations in immunotherapy for solid tumors: a review.

K M Heaton1, E A Grimm.   

Abstract

The use of cytokines alone or in combination with other cytokines or cytotoxic drugs has had a profound effect upon widely metastatic disease in many cases. However, despite the encouraging results in early trials, there is much room for improvement. Few responses to these combinations are complete, and toxicity has in some cases been quite severe. Changes in dose, route, or schedule of administration of the drugs, or the development of cytokine analogs may lead to more efficacious and less toxic regimens. In addition, new cytokines such as interleukin(IL)-7 and IL-12 are currently under investigation for potential use in future immunotherapy trials. These prospects and the use of cytokine combinations are promising advances in the treatment of human cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348559     DOI: 10.1007/bf01518513

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  62 in total

1.  Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies.

Authors:  R M Bukowski; J S Sergi; G T Budd; S Murthy; R Tubbs; V Gibson; L Bauer; J Stanley; S Gautam; J Finke
Journal:  J Immunother (1991)       Date:  1991-12

2.  IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4.

Authors:  H Stötter; M C Custer; E S Bolton; L Guedez; M T Lotze
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

3.  Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma.

Authors: 
Journal:  Cancer       Date:  1987-09-01       Impact factor: 6.860

Review 4.  Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2.

Authors:  M S Mitchell
Journal:  Semin Oncol       Date:  1992-04       Impact factor: 4.929

5.  Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.

Authors:  C M Higuchi; J A Thompson; C G Lindgren; S Gillis; M B Widmer; D E Kern; A Fefer
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

6.  Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases.

Authors:  J A Neidhart; S A Anderson; J E Harris; J J Rinehart; J Laszlo; F H Dexeus; L H Einhorn; D L Trump; P W Benedetto; R L Tuttle
Journal:  J Clin Oncol       Date:  1991-05       Impact factor: 44.544

7.  Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model.

Authors:  C S McCune; D M Marquis
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

8.  Phase I trial of interleukin-2 plus gamma-interferon.

Authors:  K A Margolin; J H Doroshow; S A Akman; L A Leong; R J Morgan; J Raschko; G Somlo; B Mills; D Goldberg; I Sniecinski
Journal:  J Immunother (1991)       Date:  1992-01

9.  Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.

Authors:  E Shiloni; P Pouillart; J Janssens; T Splinter; T Di Peri; M Symann; G J Roest; P A Palmer; C R Franks
Journal:  Eur J Cancer Clin Oncol       Date:  1989

10.  Antitumor activity of recombinant interleukin 6 in mice.

Authors:  J J Mulé; J K McIntosh; D M Jablons; S A Rosenberg
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

View more
  7 in total

Review 1.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

Review 2.  Cytokine-mediated communication: a quantitative appraisal of immune complexity.

Authors:  Grégoire Altan-Bonnet; Ratnadeep Mukherjee
Journal:  Nat Rev Immunol       Date:  2019-04       Impact factor: 53.106

3.  Targeted Delivery of IL-12 Adjuvants Immunotherapy by Oncolytic Viruses.

Authors:  Andrea Vannini; Valerio Leoni; Gabriella Campadelli-Fiume
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  [Complete remission of pulmonary metastasis from renal cell carcinoma through inhalation therapy with Interleukin-2 after unsuccessful systemic immunochemotherapy].

Authors:  K Rohrmann; J Schleypen; C Adam; A Hofstetter; M Siebels
Journal:  Urologe A       Date:  2004-10       Impact factor: 0.639

5.  Examination of lymphokines induced in mice following immunization with recombinant simian virus 40 large tumor antigen.

Authors:  R K Bright; M H Shearer; R C Kennedy
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

6.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.

Authors:  V Bronte; K Tsung; J B Rao; P W Chen; M Wang; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

Review 7.  Immunostimulatory DNA sequences and cancer therapy.

Authors:  G J Weiner
Journal:  Springer Semin Immunopathol       Date:  2000
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.